What sermorelin is. And where it comes from
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It was originally developed as a diagnostic tool and treatment for pediatric growth hormone deficiency (GHD) and approved by the FDA in 1997 under the brand name Geref. Serono withdrew the product from the US market in 2008 for commercial reasons, but it remains widely used in compounding pharmacies for off-label purposes.
Sermorelin stimulates the pituitary gland to release its own GH in a pulsatile, physiological manner, unlike direct GH injections, which suppress the natural feedback axis.
Mechanism, in plain English
Endogenous GHRH is a 44-amino-acid peptide released from the hypothalamus. It binds to GHRH receptors on pituitary somatotroph cells, triggering GH synthesis and secretion. Sermorelin (GHRH 1-29) retains the biologically active N-terminal region responsible for receptor binding and is fully active despite being truncated.
- Pituitary stimulation. Sermorelin binds GHRH receptors and triggers GH release in a pulsatile pattern that mirrors the body's natural secretory rhythm.
- Intact feedback axis. Because GH is released from the pituitary rather than administered exogenously, the somatostatin-mediated negative feedback loop remains functional.
- IGF-1 downstream. Pituitary-released GH travels to the liver and peripheral tissues, stimulating IGF-1 production, the primary mediator of GH's anabolic and tissue-repair effects.
What the evidence shows
The strongest evidence is in pediatric GHD, sermorelin demonstrated equivalent growth velocity to recombinant GH in several trials, supporting its original FDA approval. In adults, evidence is more limited:
Walker et al. 1996 (JCEM). PMID 8733135. Older adults receiving sermorelin showed increased GH pulse amplitude and improved IGF-1 levels compared to placebo.
Vittone et al. 1997 (Metabolism). PMID 10232990. Demonstrated improvements in body composition and GH secretion in older men. Sample sizes were small.
There are no large, long-term RCTs examining sermorelin for anti-aging endpoints in healthy adults. Most off-label use is supported by mechanistic plausibility and small studies rather than phase 3 trial data.
FDA status (this month)
Sermorelin was FDA-approved as Geref (sermorelin acetate injection) for treatment of idiopathic growth hormone deficiency in children. The branded product was voluntarily withdrawn from the US market in 2008. Compounded sermorelin is available through licensed compounding pharmacies. Last reviewed 2026-08-09.
Common synonyms researchers use
Sermorelin · GHRH (1-29) · Geref · Sermorelin acetate · GRF (1-29) · growth hormone-releasing factor 1-29
Safety & adverse-event landscape
Sermorelin has a well-characterized safety profile from its pediatric approval history. Common adverse effects include injection site reactions (redness, swelling, pain), flushing, and headache. Because it acts via the pituitary rather than directly supplying GH, it does not suppress the natural GHRH-GH axis. Contraindications include hypersensitivity to sermorelin or mannitol. Always consult a qualified healthcare provider.
Frequently asked questions
Want all the muscle recovery and GH peptides in one place?
The Peptexa Muscle Recovery guide covers sermorelin, CJC-1295, ipamorelin, and 28 more compounds, mechanism, evidence, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Muscle Recovery & Healing reference
31 compounds. Mechanism, evidence level, and FDA status for every one. Free PDF, no email required.
Get the Muscle Recovery & Healing Guide →